ArticleBiomedical engineering online2025
The predictive value of circulating lymphocyte subpopulation characteristics for the prognosis of patients with stage III-IV non-small cell lung cancer treated with EGFR-TKI.
Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the predictive value of circulating lymphocyte subpopulation characteristics for the prognosis of stage III-IV non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI).
methodsSeventy-two cases of stage III-IV NSCLC patients treated with EGFR-TKI were retrospectively selected as study subjects. The therapeutic effects of the patients were classified into three categories: complete remission (CR) or partial remission (PR) was classified as the remission group; Stable disease (SD) was classified as the stable disease group. Progression disease (PD) is classified as the progression disease group. The clinical data (general information and circulating lymphocyte subpopulation count) of the patients with different treatment effects were compared. The patients were followed up for 5 years, and factors influencing the progression-free survival (PFS) and overall survival (OS) were screened using the COX regression model. Receiver Operating Characteristic (ROC) was plotted to get the optimal stage value of circulating lymphocytes. Changes in PFS and OS of the patients were compared using the KM survival curve.
resultsAnalysis of circulating lymphocyte subsets showed that the counts of CD4 + CD45RA + CD62L + T cells in the three groups of patients presented a gradient distribution of remission group > stable disease group > progression disease group. The count of CD19 + B cells in the progression disease group (148.79 ± 39.62) was higher than that in the remission group (118.34 ± 36.71). CD4 + CD45RA + CD62L + T cells were an independent influencing factor of PFS in patients (P < 0.05). ROC curve analysis confirmed that the area under the curve (AUC) of CD4 + CD45RA + CD62L + T cell count for predicting the prognosis of NSCLC patients was 0.840 (95% CI) with a cut-off value of 126.47 and a Youden index of 0.570. The PFS of patients in the high-level group of CD4 + CD45RA + CD62L + T cells was significantly higher than that in the low-level group (P < 0.05).
conclusionCirculating lymphocyte subsets were associated with the therapeutic effect of stage III-IV NSCLC patients treated with EGFR-TKI and can be used as a prognostic indicator of PFS in patients treated with EGFR-TKI, but a comprehensive assessment should be made in combination with clinical factors (such as stage and TKI generation).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.